We propose that the lack of this metabolic plasticity in IDH1-mutant AML confers hyper-sensitivity to pharmacological inhibition of complex I and demonstrate that inhibition of complex I is a promising strategy for IDH1-mutant AML patients with primary ivosidenib resistance. The gene discussed is IDH1; the disease is acute myeloid leukemia.